+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Unisia"

Unisia (Amlodipine + Candesartan) - API Insight, 2022 - Product Thumbnail Image

Unisia (Amlodipine + Candesartan) - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Unisia (Amlodipine + Candesartan)- Drug Insight, 2019 - Product Thumbnail Image

Unisia (Amlodipine + Candesartan)- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Unisia market for cardiovascular drugs is a highly competitive and dynamic sector. It is composed of a wide range of pharmaceutical companies, ranging from large multinationals to small local firms. These companies are engaged in the development, manufacture, and marketing of drugs for the treatment of cardiovascular diseases. The market is characterized by a high degree of innovation, with new drugs and treatments being developed and launched on a regular basis. The Unisia market for cardiovascular drugs is also characterized by a high degree of regulation, with strict rules and regulations governing the manufacture and sale of these drugs. This ensures that the quality of the drugs is maintained and that the safety of patients is not compromised. Some of the major players in the Unisia market for cardiovascular drugs include Pfizer, Merck, Novartis, Sanofi, and AstraZeneca. These companies are engaged in the development, manufacture, and marketing of drugs for the treatment of cardiovascular diseases. Other companies in the market include GlaxoSmithKline, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more